Active transport of RB protein from the nucleus to the cytoplasm as one of the development mechanisms of HER2-positive breast cancer

Polish Journal of Pathology

Volumn 64, Issue 1, 2013, Pages 9-14

  Kowalik, Artur ^a   Kopczyński, Janusz ^a   Wypiórkiewicz, Elzbieta ^a   Góźdź, Stanisław ^a   Mezyk, Ryszard ^a   Siedlecki, Janusz Aleksander ^b  

^a HOLYCROSS CANCER CENTER   (Poland)

^b INSTITUTE OF ONCOLOGY   (Poland)

Author keywords

Active transport; Breast cancer; HER2; RB1

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; RETINOBLASTOMA PROTEIN; TUMOR MARKER;

ACTIVE TRANSPORT; ARTICLE; BREAST TUMOR; CASE CONTROL STUDY; CELL NUCLEUS; CHEMICAL STRUCTURE; COMPARATIVE STUDY; CYTOPLASM; DISEASE FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION; HUMAN; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS; PROTEIN TRANSPORT; TISSUE MICROARRAY;

BIOLOGICAL TRANSPORT, ACTIVE; BREAST NEOPLASMS; CASE-CONTROL STUDIES; CELL NUCLEUS; CYTOPLASM; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MIDDLE AGED; MODELS, MOLECULAR; PROGNOSIS; PROTEIN TRANSPORT; RECEPTOR, ERBB-2; RETINOBLASTOMA PROTEIN; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84876968523     PISSN: 12339687     EISSN: None     Source Type: Journal    
DOI: 10.5114/PJP.2013.34597     Document Type: Article

References (21)

1. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177-182.
2. Baselga J, Tripathy D, Mendelsohn J, et al. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 1996; 14: 737-744.
3. Spigel DR, Burstein HJ. HER2 overexpressing metastatic breast cancer. Curr Treat Options Oncol 2002; 3: 163-174.
4. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70.
5. Fung YK, T'Ang A. The role of the retinoblastoma gene in breast cancer development. Cancer Treat Res 1992; 61:59-68.
6. Burkhart DL, Sage J. Cellular mechanisms of tumour suppression by the retinoblastoma gene. Nat Rev Cancer 2008; 8: 671-682.
7. Jiao W, Datta J, Lin HM, et al. Nucleocytoplasmic shuttling of the retinoblastoma tumor suppressor protein via Cdk phosphorylation-dependent nuclear export. J Biol Chem 2006; 281: 38098-38108.
8. Jiao W, Lin HM, Datta J, et al. Aberrant nucleocytoplasmic localization of the retinoblastoma tumor suppressor protein in human cancer correlates with moderate/poor tumor differentiation. Oncogene 2008; 27: 3156-3164.
9. Oliveira AM, Ross JS, Fletcher JA. Tumor suppressor genes in breast cancer: the gatekeepers and the caretakers. Am J Clin Pathol 2005; 124 Suppl:S16-28.
10. Pinto AE, Andre S, Laranjeira C, et al. Correlations of cell cycle regulators (p53, p21, pRb and mdm2) and c-erbB-2 with biological markers of proliferation and overall survival in breast cancer. Pathology 2005; 37: 45-50.
11. Kononen J, Bubendorf L, Kallioniemi A, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998; 4: 844-847.
12. Chen N, Zhou Q. Constructing tissue microarrays without prefabricating recipient blocks: a novel approach. Am J Clin Pathol 2005; 124: 103-107.
13. Pires AR, Andreiuolo Fda M, de Souza SR. TMA for all: a new method for the construction of tissue microarrays without recipient paraffin block using custom-built needles. Diagn Pathol 2006; 1:14.
14. Stefansson OA, Jonasson JG, Olafsdottir K, et al. CpG island hypermethylation of BRCA1 and loss of pRb as co-occurring events in basal/triple-negative breast cancer. Epigenetics 2011; 6: 638-649.
15. van Deursen JM. Rb loss causes cancer by driving mitosis mad. Cancer Cell 2007; 11: 1-3.
16. Ellsworth RE, Ellsworth DL, Patney HL, et al. Amplification of HER2 is a marker for global genomic instability. BMC Cancer 2008; 8:297.
17. Ago K, Saegusa Y, Nishimura J, et al. Involvement of glycogen synthase kinase-3beta signaling and aberrant nucleocytoplasmic localization of retinoblastoma protein in tumor promotion in a rat two-stage thyroid carcinogenesis model. Exp Toxicol Pathol 2010; 62: 269-280.
18. Liao DJ, Dickson RB. c-Myc in breast cancer. Endocr Relat Cancer 2000; 7: 143-164.
19. Blancato J, Singh B, Liu A, et al. Correlation of amplification and overexpression of the c-myc oncogene in high-grade breast cancer: FISH, in situ hybridisation and immunohistochemical analyses. Br J Cancer 2004; 90: 1612-1619.
20. Musgrove EA, Sutherland RL. Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer 2009; 9: 631-643.
21. Prat A, Baselga J. The role of hormonal therapy in the management of hormonal-receptor-positive breast cancer with coexpression of HER2. Nat Clin Pract Oncol 2008; 5: 531-542.